Martel P, David J M, Zervoudis S, Riba M, Bugat R
J Gynecol Obstet Biol Reprod (Paris). 1985;14(5):633-9.
The authors report their experience in 35 cases of second-look laparotomy performed on 35 patients in the Claudius Regaud Centre. The actuarial survival rate at 3 years of patients who had undergone this surgery has been shown to be 41% as against 13% for all Stage III and IV cases randomly taken in this same period (194 cases). Indications for a second-look laparotomy are generally reserved for patients who have responded to chemotherapy after a mean of 6 treatments unless there in an obvious indication to go in. The reasons for this procedure include the idea of assessing completely the state of affairs and if necessary carrying out a large excision operation, knowing full well that the results will depend mainly on the quality of the first treatment given. Survival after second-look laparotomy depends on the mass of neoplastic tissue that is left behind, its size and its position in the peritoneal cavity or in the lumbo-aortic lymph nodes. This makes it possible to define that privileged group of patients that have a good prognosis. These patients who can be cured are those who have no disease in the peritoneal cavity or in the lymph glands. The combination of different ways of treating residual disease in the peritoneum or behind the peritoneum are derived from decisions made following second-look laparotomy. There is no place for radiotherapy of the abdomen and pelvis when there is residual lymph gland disease.
作者报告了他们在克劳迪乌斯·雷高德中心对35例患者进行二次剖腹探查术的经验。接受该手术的患者3年实际生存率为41%,而同期随机选取的所有Ⅲ期和Ⅳ期病例(194例)的3年实际生存率为13%。二次剖腹探查术的指征通常保留给平均接受6次治疗后对化疗有反应的患者,除非有明显的手术指征。进行该手术的原因包括全面评估病情,必要时进行大范围切除手术,同时清楚地知道结果将主要取决于首次治疗的质量。二次剖腹探查术后的生存率取决于残留肿瘤组织的量、其大小以及在腹腔或腰主动脉淋巴结中的位置。这使得确定预后良好的特定患者群体成为可能。这些能够治愈的患者是那些腹腔或淋巴结中没有疾病的患者。腹膜或腹膜后残留疾病的不同治疗方法组合源自二次剖腹探查术后做出的决策。当存在残留淋巴结疾病时,腹部和盆腔放疗没有用。